BAY1436032: IDH1 inhibition in IDH1-mutated AML

preview_player
Показать описание
Michael Heuser, MD, of Hannover Medical School, Hannover, Germany, reports the Phase I safety and efficacy results of the mutant IDH1 inhibitor, BAY1436032 in subjects with IDH1-mutated acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Michael Heuser
  3. Institution: Hannover Medical School
  4. Event: VJVirtual
  5. Event: EHA 2020
  6. Format: Interview
Рекомендации по теме
BAY1436032: IDH1 inhibition 0:03:01

BAY1436032: IDH1 inhibition in IDH1-mutated AML

Treatment strategies for 0:01:53

Treatment strategies for patients with IDH1/2-mutated AML ineligible for intensive chemotherapy

How do targeted 0:01:27

How do targeted treatments for IDH1 and IDH2 mutations work in acute myeloid leukemia (AML)?

IDH1 inhibitor ivosidenib 0:01:48

IDH1 inhibitor ivosidenib for the treatment of relapsed/ refractory AML

Targeting IDH1/2 in 0:06:10

Targeting IDH1/2 in AML

The impact of 0:02:08

The impact of IDH mutations on the outcomes of patients with AML & inhibitors under investigatio...

Phase I study 0:01:35

Phase I study of LY3410738: a first-in-class IDH1-R132 inhibitor

The prognostic impact 0:02:53

The prognostic impact of IDH mutations and the role of IDH inhibitors in MDS

IDH Inhibitors for 0:02:05

IDH Inhibitors for Cholangiocarcinoma

IDH inhibitors 0:01:59

IDH inhibitors

Clinical challenges with 0:03:49

Clinical challenges with new and emerging IDH1/IDH2 inhibito

Olutasidenib monotherapy in 0:03:48

Olutasidenib monotherapy in patients with R/R mutant IDH1 AML

IDH Inhibition in 0:01:33

IDH Inhibition in Acute Myeloid Leukemia –Emergence of a New Therapeutic Era

LY3410738: a first-in-class 0:01:52

LY3410738: a first-in-class covalent inhibitor of mutant IDH1 in CCA

Implications of Rapid 0:37:51

Implications of Rapid IDH1/IDH2 Testing for Liquid and Solid Tumors

Acute Myeloid Leukemia: 0:52:20

Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical Pathways

Are IDH1/IHD2 mutations 0:02:10

Are IDH1/IHD2 mutations more or less common in MDS than in AML?

ClarIDHy: ivosidenib in 0:01:29

ClarIDHy: ivosidenib in CCA

Treatment approaches in 0:32:55

Treatment approaches in AML

Leveraging Genomics and 0:41:40

Leveraging Genomics and Biology for Non-invasive Metabolic Imaging and Therapy for Brain Tumors

USMLE FIRST AID 0:14:25

USMLE FIRST AID STEP 2021 Exotoxin 10b (Diphtheria toxin, Pseudomonas toxin, Shiga toxin, O157:H7)

Oncotarget: Smurf2 Regulation 0:00:46

Oncotarget: Smurf2 Regulation of HIF-1α in Cancer Cells

Role of ketogenic 0:41:23

Role of ketogenic metabolic therapy in malignant glioma: A systematic review

SSBMT Webinar Series 0:59:40

SSBMT Webinar Series - How I Treat AML incorporating MRD assessments - 14 November